Private company

CymaBay Therapeutics (United States)

In its 2024 annual report the company says: “We are a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with liver and other chronic diseases with high unmet medical need. Our lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator activated receptor delta (PPAR d ), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation and fibrosis.”7 It was founded in 1991.1 It is headquartered in Newark.1

Last updated Oct 20, 2026.

Overview

Jan 1, 1991Founded1
  • IndustryPharmaceutical Preparations1
  • HeadquartersNewark1
  • Websitewww.cymabay.com
  • Legal formDelaware corporation1
  • Incorporated inDE4
  • Business address7575 Gateway Boulevard, Suite 110, Newark, Ca 945604
  • Filer categoryLarge accelerated filer, Smaller reporting company4
  • LEI549300YT9GNL852E7F843
  • StatusActive3
  • LEI statusLapsed (not renewed)3
  • Registered addressC/O The Prentice-Hall Corporation System, Inc., 19808 Wilmington, United States3
  • Registered withDivision of Corporations, Department of State, 21746053

See how the biggest companies compare on our leaderboards

CymaBay Therapeutics (United States) image from its website
Image: cymabay.com6

We are a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with liver and other chronic diseases with high unmet medical need.7 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-327.2%Operating margin8
-339.1%Net margin8
-36.1%Return on equity8
-$73.0MFree cash flow8

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Research and development81¢$80.8M
  • Interest19¢$18.9M

Out of $31.1M in revenue.8 The company lost money this year.

Financial statements

Revenue98$31.1M in 2023+211% since 2017
0$10.0M$20.0M$30.0M$40.0M2017: $10.0M$10.0M20172021: $0$020212022: $0$020222023: $31.1M$31.1M2023
Operating income91011128-$101.7M in 2023+377% since 2017
-$150.0M-$100.0M-$50.0M02017: -$21.3M-$21.3M20172018: -$72.5M-$72.5M2018+240%2019: -$108.2M-$108.2M2019+49%2020: -$52.6M-$52.6M2020−51%2021: -$87.6M-$87.6M2021+66%2022: -$93.1M-$93.1M2022+6%2023: -$101.7M-$101.7M2023+9%
Net income91011128-$105.4M in 2023+282% since 2017
-$150.0M-$100.0M-$50.0M02017: -$27.6M-$27.6M20172018: -$72.5M-$72.5M2018+163%2019: -$102.8M-$102.8M2019+42%2020: -$51.0M-$51.0M2020−50%2021: -$90.0M-$90.0M2021+77%2022: -$106.0M-$106.0M2022+18%2023: -$105.4M-$105.4M2023−1%
Fiscal year2017201820192020202120222023
Revenue$10.0M9$08$08$31.1M8
Research and development$18.9M9$58.1M10$83.8M11$35.9M12$64.5M8$68.0M8$80.8M8
Operating expenses$87.6M8$93.1M8$132.8M8
Operating income-$21.3M9-$72.5M10-$108.2M11-$52.6M12-$87.6M8-$93.1M8-$101.7M8
Interest$1.1M9$336.0K10$2.6M8$14.9M8$18.9M8
Income tax$09$09$011$012$08$08$08
Net income-$27.6M9-$72.5M10-$102.8M11-$51.0M12-$90.0M8-$106.0M8-$105.4M8
Earnings per share-$0.799-$1.2510-$1.5311-$0.7412-$1.278-$1.218-$0.998
Earnings per share (diluted)-$0.799-$1.2610-$1.5310-$1.278-$1.218-$0.998
Shares (weighted, basic)71.1M shares887.8M shares8106.2M shares8
Shares (weighted, diluted)71.1M shares887.8M shares8106.2M shares8

Compare CymaBay Therapeutics (United States) with another company

Corporate structure

CymaBay Therapeutics (United States) sits at the top of its group. 4 entities, 4 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of CymaBay Therapeutics (United States)

  • Avoro Capital Advisors LLC Filed SC 13G/A on CymaBay Therapeutics (United States), latest Feb 14, 2024 (2 filings since Feb 11, 2022)
  • Commodore Capital LP Filed SC 13G/A on CymaBay Therapeutics (United States), latest Feb 14, 2024 (3 filings since Feb 14, 2022)
  • Janus Henderson Group Ltd. Filed SC 13G on CymaBay Therapeutics (United States), latest Feb 14, 2024
  • PERCEPTIVE ADVISORS LLC Filed SC 13G/A on CymaBay Therapeutics (United States), latest Feb 14, 2024 (2 filings since Mar 10, 2023)
  • TCG Crossover GP I, LLC Filed SC 13G/A on CymaBay Therapeutics (United States), latest Feb 13, 2024 (2 filings since Feb 14, 2023)
  • VANGUARD GROUP INC Filed SC 13G on CymaBay Therapeutics (United States), latest Feb 13, 2024
  • RA CAPITAL MANAGEMENT, L.P. Filed SC 13G on CymaBay Therapeutics (United States), latest Sep 22, 2023
  • ADAGE CAPITAL PARTNERS GP, L.L.C. Filed SC 13G on CymaBay Therapeutics (United States), latest Sep 11, 2023
  • Boxer Capital, LLC Filed SC 13G/A on CymaBay Therapeutics (United States), latest Feb 14, 2022
  • TCG Crossover Management, LLC Filed SC 13G on CymaBay Therapeutics (United States), latest Nov 29, 2021
  • CymaBay Therapeutics (United States) Hayward, California, United States
    • CymaBay Canada, Ltd. Subsidiary · Canada
    • CymaBay Ireland, Limited Subsidiary · Ireland
    • CymaBay UK, Ltd. Subsidiary · United Kingdom

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What CymaBay Therapeutics (United States) reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$3.9M8 Dec 31, 2023$3.5M8 Dec 31, 2022+12.9%
Accumulated depreciation$3.4M8 Dec 31, 2023$2.7M8 Dec 31, 2022+24.8%
Property and equipment, net$465.0K8 Dec 31, 2023$701.0K8 Dec 31, 2022−33.7%
Finance-lease assets$458.0K8 Dec 31, 2023
Operating-lease assets (leased space)$4.8M8 Dec 31, 2023$169.0K15 Dec 31, 2022+2741.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$206.5M8 Dec 31, 2023$20.3M8 Dec 31, 2022+917.9%
Marketable securities, current$187.7M8 Dec 31, 2023$115.2M8 Dec 31, 2022+63.0%
Marketable securities, non-current$21.9M8 Dec 31, 2023$08 Dec 31, 2022

Leadership

Who has led CymaBay Therapeutics (United States), and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Wart Harold Van2013–2017
  2. Sujal Shah2017–2024

President

  1. Wart Harold Van2013–2017
  2. Sujal Shah2017–2020
  3. Charles McWherter2023–2024

Chief financial officer

  1. Sujal Shah2013–2017
  2. Harish Shantharam2023–2024
1995200020052010201520202025
Board members and other officers (26)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • CymaBay Canada, Ltd. Canada5
  • CymaBay Ireland, Limited Ireland5
  • CymaBay UK, Ltd. United Kingdom5

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • METABOLEX, INC.Jul 21, 2009 to Nov 10, 20094
  • METABOLEX INCFeb 19, 2002 to Mar 5, 20094

Timeline

  1. Mar 22, 20248-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights46
  2. Mar 20, 20248-K Executive or director change47
  3. Feb 12, 20248-K Entered a material agreement; Bylaws or fiscal year changed; Regulation FD disclosure48
  4. Jan 26, 20248-K Executive or director change49
  5. Dec 21, 20238-K Other events50
  6. Dec 13, 20238-K Entered a material agreement51
  7. Sep 12, 20238-K Other events52
  8. Sep 11, 20238-K Other events53
  9. Jun 6, 20238-K Shareholder vote54
  10. May 9, 20238-K Executive or director change55
  11. Mar 16, 20238-K Results of operations56
  12. Mar 13, 20238-K Regulation FD disclosure57
  13. May 1, 2017New chief executive Sujal Shah becomes CEO16
  14. Oct 11, 2013New chief executive Wart Harold Van becomes CEO17
  15. Jan 1, 1991Founded Founded1

Calendar

When it reported results

  1. Mar 16, 2023Reported quarterly or annual results56

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

255 filings to the SEC since October 2021: 3 annual reports, 7 quarterly reports, 21 major events, 93 insider forms, 18 large holders, 113 other. The latest 20:

  1. Apr 1, 202415-12G EDGAR
  2. Mar 28, 2024EFFECT EDGAR
  3. Mar 28, 2024EFFECT EDGAR
  4. Mar 28, 2024EFFECT EDGAR
  5. Mar 28, 2024EFFECT EDGAR
  6. Mar 28, 2024EFFECT EDGAR
  7. Mar 22, 202425-NSE EDGAR
  8. Mar 22, 2024S-8 POS EDGAR
  9. Mar 22, 2024S-8 POS EDGAR
  10. Mar 22, 2024S-8 POS EDGAR
  11. Mar 22, 2024S-8 POS EDGAR
  12. Mar 22, 2024S-8 POS EDGAR
  13. Mar 22, 2024S-8 POS EDGAR
  14. Mar 22, 2024S-8 POS EDGAR
  15. Mar 22, 2024S-8 POS EDGAR
  16. Mar 22, 2024S-8 POS EDGAR
  17. Mar 22, 2024S-8 POS EDGAR
  18. Mar 22, 2024S-8 POS EDGAR
  19. Mar 22, 2024S-8 POS EDGAR
  20. Mar 22, 2024S-8 POS EDGAR

The 255 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

38 open-market trades by officers, directors and large owners since October 2021: 2 buys and 36 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Feb 12, 2024Dorling JanetDirectorSale6,000$31.97$191.8KForm 4
Jan 19, 2024McWherter CharlesPresident of R&DSale18,403$23.67$435.7KForm 4
Jan 16, 2024Menold DanielVice President, FinanceSale10,000$23.58$235.8KForm 4
Jan 16, 2024Quinlan Paul TGeneral CounselSale5,000$23.58$117.9KForm 4
Jan 10, 2024Dorling JanetDirectorSale6,000$23.86$143.2KForm 4
Dec 18, 2023McWherter CharlesPresident of R&DSale11,332$21.48$243.5KForm 4
Dec 15, 2023Menold DanielVice President, FinanceSale21,497$21.99$472.6KForm 4
Dec 15, 2023Quinlan Paul TGeneral CounselSale5,000$21.98$109.9KForm 4
Dec 11, 2023Shah SujalChief Executive OfficerSale64,865$20.00$1.3MForm 4
Dec 11, 2023Dorling JanetDirectorSale6,000$20.07$120.4KForm 4
Nov 17, 2023McWherter CharlesPresident of R&DSale11,342$18.28$207.3KForm 4
Nov 15, 2023Menold DanielVice President, FinanceSale0Form 4
Nov 15, 2023Quinlan Paul TGeneral CounselSale5,000$17.38$86.9KForm 4
Nov 13, 2023Shah SujalChief Executive OfficerSale64,863$15.89$1.0MForm 4
Nov 10, 2023Dorling JanetDirectorSale7,000$15.24$106.7KForm 4
Oct 18, 2023McWherter CharlesPresident of R&DSale21,743$14.07$305.9KForm 4
Oct 16, 2023Menold DanielVice President, FinanceSale0Form 4
Oct 16, 2023Quinlan Paul TGeneral CounselSale5,000$13.76$68.8KForm 4
Oct 9, 2023Shah SujalChief Executive OfficerSale64,861$14.20$921.0KForm 4
Sep 29, 2023EMSTER KURT VONDirectorSale15,921$15.68$249.6KForm 4

All 38 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How CymaBay Therapeutics (United States) is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCymaBay Therapeutics, Inc.2
  • CIK0001042074
  • Employer ID (EIN)94-31035612
  • Filer statusLarge accelerated filer<br>smaller reporting company2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address7575 Gateway Boulevard, Suite 110, Newark, CA 945602
  • Phone510-293-88002
  • Shares outstanding114,724,381 as of Jan 31, 20248
  • Public float$954.6M as of Jun 30, 20238
  • On EDGAR sinceFeb 19, 20022
  • Filings780 in all: 4 (291), 8-K (79), 144 (45), SC 13G/A (45), SC 13G (35), 3 (33), 10-Q (31), S-8 POS (24)2
    All 55 form types

    424B5 (19), DEFA14A (14), UPLOAD (14), EFFECT (13), S-8 (13), 10-K (11), CORRESP (10), DEF 14A (10), CT ORDER (9), POS AM (6), REGDEX/A (6), SC 14D9/A (6), S-3 (5), SC TO-T/A (5), 10-12G/A (4), REGDEX (4), 424B3 (3), D (3), SC 13D/A (3), SC TO-C (3), SC14D9C (3), 4/A (2), D/A (2), POSASR (2), PREC14A (2), S-1 (2), S-1/A (2), S-3ASR (2), 10-12G (1), 10-K/A (1), 10-Q/A (1), 15-12G (1), 25-NSE (1), 3/A (1), 424B4 (1), 8-A12B (1), 8-K/A (1), ARS (1), CERTNAS (1), PRE 14A (1), PRER14A (1), PRRN14A (1), S-1MEF (1), S-3/A (1), SC 13D (1), SC 14D9 (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) Feb 28, 2024
    Quarterly report (10-Q) Nov 7, 2023
    Proxy statement (DEF 14A) Apr 19, 2023
    Latest 8-K (8-K) Mar 22, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
    SEC EDGAROther events
  51. 51
  52. 52
    SEC EDGAROther events
  53. 53
    SEC EDGAROther events
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67